- Ixion Names Kessler VP Corporate Development
-
 ALACHUA, FL. January 3, 2001 - Louis G. Kessler, PhD,
- has joined Ixion, a development stage biotech company, as Vice President, Corporate Development.
- Kessler will play a key role in Ixion's future. He is responsible for managing Ixion's intellectual property and technology transfer activities; identifying potential academic and commercial collaborators; negotiating in-license agreements and collaboration agreements with major pharmaceutical or biotech companies; assisting in the preparation of the strategic and product development planning; compiling competitive intelligence; and providing marketing input to development scientists.
- Before joining Ixion, Kessler was director of intellectual properties and technology transfer at Univax Biologics/Nabi, a bio-pharmaceutical company. Prior to that, he served as science advisor to a Washington, D.C. law firm and as a patent examiner in the U.S. Patent and Trademark Office. Kessler received his Ph.D. in molecular and population genetics from the University of Georgia in 1984 and was a postdoctoral fellow at the University of Texas Southwestern Medical Center at Dallas.
- Alachua, Fla.-based Ixion is the world's leader in developing diagnostic and prevention options for oxalate-related disorders, such as kidney stones, primary hyperoxaluria, Crohn's Disease, and cystic fibrosis. Ixion also is developing cell therapy products to treat diabetes. The Company received the 2000 National Tibbetts Award from the SBA for excellence in research.
- "We are delighted to have Dr. Kessler come onboard. His experience in the biotech industry is ideally suited to handle the responsibilities of this position. Not only has he held senior management positions in a major biotech company, but he also has extensive research experience. Dr. Kessler has the insight necessary to balance the scientific and business aspects of a biotech company," said Weaver Gaines, Ixion chairman and CEO.
- For more information about Ixion, visit www.ixion-biotech.com or call 904-418-1428.
- This news release includes forward-looking statements involving risks and uncertainties, such as risks associated with pre-clinical and clinical development in the biotechnology industry, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments and costs of developing, producing and selling products.
- Contacts:
-
-
-
-
-
-
-
- Lisette Hilton
561-392-5649 (voice)
561-392-7496 (fax)
- Info@ixion-biotech.com
-
- Weaver H. Gaines
Chairman and Chief Executive Officer
Ixion Biotechnology, Inc.
13709 Progress Blvd.,Box 13
Alachua, FL 32615
386-418-1428 (voice)
386-418-1583 (fax)
Info@ixion-biotech.com
-
-
|
